Anxiolytic and antidepressant actions of somatostatin: the role of sst2 and sst3 receptors
- First Online:
- 243 Downloads
Rationale and objectives
Somatostatin is a cyclic polypeptide that inhibits the release of a variety of regulatory hormones (e.g., growth hormone, insulin, glucagon, and thyrotropin). Somatostatin is also widely distributed within the central nervous system (CNS), acting both as a neurotransmitter and as a neuromodulator. Recently, we showed that intracerebroventricular (i.c.v.) administration of somatostatin reduced anxiety-like and depression-like behaviors in animal models. The somatostatin receptor subtypes that are involved in these behavioral effects, however, have not been investigated. In the CNS, the neurotransmitter actions of somatostatin are mediated through five G-protein coupled receptors (sst1 to sst5).
Materials and methods
We examined the behavioral effects of i.c.v. microinfusions of different doses of selective agonists of each of the five somatostatin receptor subtypes. Their behavioral effects were assessed in the elevated plus-maze and the forced swim apparatus, rodent models of anxiolytic and antidepressant drug effects, respectively.
Anxiety-like behavior was reduced following i.c.v. infusions of a selective sst2 receptor agonist, but not after infusions of the other four receptor agonists. An antidepressant-like effect was observed following infusions of either sst2 or sst3 agonists.
The results add to our nascent understanding of the role of somatostatin in anxiety- and depression-like behavior and suggest a clinical role for somatostatin agonists for the simultaneous treatment of anxiety and depression, which are often comorbid.
KeywordsSomatostatin Anxiety Depression Agonist Plus-maze Swim test
- Beranek L, Obal F, Taishi P, Bodosi B, Laczi F, Krueger JM (1997) Changes in rat sleep after single and repeated injections of the long-acting somatostatin analog octreotide. Am J Physiol Regul Integr Comp Physiol 273:R1484–R1491Google Scholar
- Chrubasik S, Ziegler R (1996) Does the somatostatin analogue pctreotide have a role in pain relief? Pain Clin 8:369–375Google Scholar
- De Jong M, Breeman WAP, Bernard HF, Kooij PPM, Slooter GD, Van Eijck CHJ, Kwekkeboom DJ, Valkema R, Macke HR, Krenning EP (1999) Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues. Quart J Nucl Med 43:356–366Google Scholar
- Dournaud P, Slama A, Beaudet A et al (2000) Somatostatin receptors. In: Quirion R, Björklund A, Hökfelt T (eds) Handbook of chemical neuroanatomy. Elsevier, Amsterdam, pp 1–43Google Scholar
- Kong H, Depaoli AM, Breder CD, Yasuda K, Bell GI, Reisine T (1994) Differential expression of messenger-RNAs for somatostatin receptor subtypes sstr1, sstr2 and sstr3 in adult-rat brain - analysis by rna blotting and in-situ hybridization histochemistry. Neuroscience 59:175–184PubMedCrossRefGoogle Scholar
- Low MJ, Juarez R, Rubinstein M, Carey K (1998) Impaired learning and memory in somatostatin-deficient mice. Brain Res 809:P311Google Scholar
- Marazioti A, Spyraki C, Thermos K (2006) Somatostatin (SRIF) infused in the globus pallidus increases locomotor activity and cFos expression in rat brain areas implicated in motor control. Acta Pharmacol Sin 27:S428Google Scholar
- Moneta D, Richichi C, Aliprandi M, Dournoud P, Dutar P, Billard JM, Carlo AS, Viollet C, Hannon JP, Fehlmann D, Nunn C, Hoyer D, Epelbaum J, Vezzani A (2002) Somatostatin receptor subtypes 2 and 4 affect seizure susceptibility and hippocampal excitatory neurotransmission in mice. Eur J NeuroSci 16:843–849PubMedCrossRefGoogle Scholar
- Obal F, Hajdu I, Gardi J, Szentirmai E, Krueger JM (2003) GHRH mediates somatostatin actions on sleep. Sleep 26:A18Google Scholar
- Perez J, Vezzani A, Civenni G, Tutka P, Rizzi M, Schuepbach E, Hoyer D (1995) Functional effects of d-Phe-c[Cys-Tyr-d-Trp-Lys-Val-Cys]-Trp-NH2 and differential changes in somatostatin receptor messenger RNAs, binding sites and somatostatin release in kainic acid-treated rats. Neuroscience 65:1087–1097PubMedCrossRefGoogle Scholar
- Porsolt RD, Lenegre A, McArthur RA (1991) Pharmacological models of depression. In: Oliver B, Mos J, Sanger JL (eds) Animal models in psychopharmacology. Birkhauser, Basel, pp 137–159Google Scholar
- Rohrer SP, Birzin ET, Mosley RT, Berk SC, Hutchins SM, Shen DM, Xiong YS, Hayes EC, Parmar RM, Foor F, Mitra SW, Degrado SJ, Shu M, Klopp JM, Cai SJ, Blake A, Chan WWS, Pasternak A, Yang LH, Patchett AA, Smith RG, Chapman KT, Schaeffer JM (1998) Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science 282:737–740PubMedCrossRefGoogle Scholar
- Tashev R, Belcheva I (2008) Learning and memory effects of somatostatin microinjected into the rat dorsal neostriatum. Comptes Rendus de l’Academie Bulgare des Sciences 61:557–562Google Scholar
- Treit D, Degroot A, Shah A (2003) Animal models of anxiety and anxiolytic drug action. In: Kasper S, den Boer JA, Ad Sitsen JM (eds) Handbook of depression and anxiety, vol 2nd. New York, Marcel-DekkerGoogle Scholar
- Viollet C, Vaillend C, Videau C, Bluet-Pajot MT, Ungerer A, L’Heritier A, Kopp C, Potier B, Billard JM, Schaeffer J, Smith RG, Rohrer SP, Wilkinson H, Zheng H, Epelbaum J (2000) Involvement of sst2 somatostatin receptor in locomotor, exploratory activity and emotional reactivity in mice. Eur J NeuroSci 12:3761–3770PubMedCrossRefGoogle Scholar
- Willner P (1994) Animal models of depression. In: den Boer JA, Ad Sitsen JM (eds) Handbook of depression and anxiety. Marcel Dekker, New York, pp 291–316Google Scholar